John T. Treace, 10% Owner, Director, Chief Executive Officer, on May 26, 2026, executed a purchase for 115,520 shares in Treace Medical Concepts (TMCI) for $340,589. Following the Form 4 filing with the SEC, Treace has control over a total of 12,597,962 common shares of the company, with 7,273,833 shares held directly and 5,324,129 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1630627/000119312526245341/xslF345X05/ownership.xml
Martine A Rothblatt, Director, Chairperson & CEO, on May 27, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,466,283. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000063/xslF345X05/primarydocument.xml
Robert I Blum, Director, President & CEO, on May 27, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $579,075. Following the Form 4 filing with the SEC, Blum has control over a total of 396,996 common shares of the company, with 392,830 shares held directly and 4,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000063/xslF345X05/form4.xml
Edward Meyercord, Director, President and CEO, on May 26, 2026, sold 100,000 shares in Extreme Networks (EXTR) for $2,609,590. Following the Form 4 filing with the SEC, Meyercord has control over a total of 1,721,902 common shares of the company, with 1,721,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1078271/000143774926018754/xslF345X05/rdgdoc.xml